{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:37:27Z","timestamp":1783075047572,"version":"3.54.6"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1001\/jamaoncol.2018.6278","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T13:30:41Z","timestamp":1551360641000},"page":"715","source":"Crossref","is-referenced-by-count":52,"title":["Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation"],"prefix":"10.1001","volume":"5","author":[{"given":"Abraham S.","family":"Kanate","sequence":"first","affiliation":[{"name":"Section of Hematology and Oncology, West Virginia University, Morgantown, West Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Program for Comparative Effectiveness Research, University of South Florida Morsani College of Medicine, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, LMU Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Hospitalo-Universitaire Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Fondazione Istituto Nazionale dei Tumori Milano University of Milano, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bredeson","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Bone Marrow Transplant Programme, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, The University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Hematology Department, Institut Catal\u00e0 d'Oncologia-Hospitalet, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Inwards","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation Program, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishitha","family":"Reddy","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[{"name":"Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Robinson","sequence":"additional","affiliation":[{"name":"University Hospital Bristol NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A.","family":"Abutalib","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Cancer Treatment Centers of America, Zion, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vose","sequence":"additional","affiliation":[{"name":"Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Gopal","sequence":"additional","affiliation":[{"name":"University of Washington, Fred Hutchinson Cancer Research Center, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"University of Washington, Fred Hutchinson Cancer Research Center, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Carpenter","sequence":"additional","affiliation":[{"name":"University of Washington, Fred Hutchinson Cancer Research Center, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee"},{"name":"Center for International Blood and Marrow Transplant Research, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"csc180002r1","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell\u00a0transplantation: Guidelines from the American Society for\u00a0Blood and Marrow Transplantation.","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"csc180002r2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/bmt.2015.6","article-title":"Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.","volume":"50","author":"Sureda","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"csc180002r3","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.bbmt.2017.05.035","article-title":"Current use and trends in hematopoietic cell transplantation in the United States.","volume":"23","author":"D\u2019Souza","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"csc180002r4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/s41409-018-0153-1","article-title":"Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report.","volume":"53","author":"Passweg","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"csc180002r5","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","article-title":"Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.","volume":"31","author":"Pettengell","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9980","key":"csc180002r6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"13","key":"csc180002r7","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma.","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"36","key":"csc180002r8","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"issue":"25","key":"csc180002r9","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1200\/JCO.2012.42.0489","article-title":"American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology.","volume":"30","author":"Loblaw","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"csc180002r10","doi-asserted-by":"publisher","first-page":"i","DOI":"10.3310\/hta2030","article-title":"Consensus development methods, and their use in clinical guideline development.","volume":"2","author":"Murphy","year":"1998","journal-title":"Health Technol Assess"},{"issue":"7","key":"csc180002r11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","article-title":"Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party.","volume":"98","author":"Montoto","year":"2013","journal-title":"Haematologica"},{"issue":"19","key":"csc180002r12","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1200\/JCO.2013.54.0955","article-title":"Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.","volume":"32","author":"Ramakrishna","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"csc180002r14","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/bmt.2015.177","article-title":"A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.","volume":"50","author":"Satwani","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"csc180002r15","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1002\/cncr.30818","article-title":"Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.","volume":"123","author":"Hui","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"csc180002r16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma.","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"csc180002r17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(17)30913-0","article-title":"Salvage regimens for Hodgkin\u2019s lymphoma in the brentuximab vedotin era.","volume":"19","author":"Vitolo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"csc180002r18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study.","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"csc180002r19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"11","key":"csc180002r20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"23","key":"csc180002r21","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"issue":"3","key":"csc180002r22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/leu.2013.332","article-title":"Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma.","volume":"28","author":"Dietrich","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"csc180002r23","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma.","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"csc180002r24","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","article-title":"Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).","volume":"34","author":"Rummel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"csc180002r25","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1093\/annonc\/mdv364","article-title":"Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.","volume":"26","author":"Graf","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"csc180002r26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"22","key":"csc180002r27","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"csc180002r28","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN Study.","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14","key":"csc180002r29","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma.","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"csc180002r30","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00277-016-2705-z","article-title":"Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.","volume":"95","author":"Bourcier","year":"2016","journal-title":"Ann Hematol"},{"issue":"17","key":"csc180002r31","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"key":"csc180002r32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ejca.2017.01.021","article-title":"Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.","volume":"76","author":"Vidal","year":"2017","journal-title":"Eur J Cancer"},{"issue":"23","key":"csc180002r33","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"csc180002r34","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare study and Center for International Blood and Marrow Transplant research analysis.","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"csc180002r35","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/cncr.v124.12","article-title":"Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer"},{"issue":"6","key":"csc180002r36","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group.","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"csc180002r37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance.","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"csc180002r13","volume-title":"Grading the strength of a body of evidence when assessing health care interventions for the effective health care program of the Agency for Healthcare Research and Quality: an update","author":"Berkman","year":"2013"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaoncology\/article-pdf\/5\/5\/715\/17575199\/jamaoncology_kanate_2019_sc_180002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T12:57:00Z","timestamp":1557406620000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.6278"}},"subtitle":["A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT"],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.6278","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}